arrow
R

Ran Reshef

blood and marrow transplant clinical trials network
H指数:42
被引数:8,519

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Early treatment failure after ciltacabtagene autoleucel in multiple myeloma with high-risk features: implications for risk-informed care

具有高危特征的多发性骨髓瘤在应用cilta-cabtagene autoleucel治疗后早期失败:对风险知情护理的启示

2026-10-220
OAAI
Spatiotemporal single-cell profiling reveals T cell clonal dynamics and phenotypic plasticity in human graft-versus-host disease

空间-时间单细胞图谱揭示人类移植物抗宿主病中T细胞克隆动态和表型可塑性

2026-09-170
PRE
Phase II Study of Posttransplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After HLA-Mismatched Unrelated Donor Reduced Intensity Transplantation: Results From the ACCESS Trial Expansion Cohort

HLA错配无关供者减低强度移植后移植抗宿主病预防的术后环磷酰胺方案II期研究:ACCESS试验扩展队列结果

2026-09-010
OAAI
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia

CAR HEMATOTOX 独立预测急性淋巴细胞白血病接受CD19 CAR-T疗法后的结局

2025-10-080
OAAI
Performance of treatment response assessment at day 7 by baseline acute graft-vs-host disease severity

基于基线急性移植物抗宿主病严重程度的第7天治疗反应评估表现

2025-09-250
PRE
The MAGIC Composite Response: A Novel Endpoint Integrating Clinical and Biomarker Parameters for Acute GVHD

MAGIC复合应答:一种整合临床和生物标志物参数的急性GVHD新型终点指标

2025-08-190
OAAI
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy

Dhakal, B.; Akhtar, O.S.; Fandrei, D.; Jensen, A.; Banerjee, R.; Pan, D.; Richard, S.; Friend, R.; Rees, M.J.; Costello, P.; 等. 多发性骨髓瘤的序贯靶向治疗:Talquetamab,一种GPRC5D双特异性抗体,作为BCMA CAR-T细胞疗法的桥梁。Blood 2025. [Google Scholar] [CrossRef]

Blood
IF23.1
2025-08-050
PRE
Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group

移植物抗宿主病治疗期间的系列临床和生物标志物监测确定了不同的风险阶层,包括超低风险组

2025-01-010
PRE
Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Idecabtagene Vicleucel (Ide-cel) 在对新诊断多发性骨髓瘤(NDMM)且对一线自体干细胞移植(ASCT)反应不足的患者(Pts)中的研究:KarMMa-2研究队列2c的扩展随访

BLOOD
IF23.1
2024-11-050
PRE
Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above

Brexucabtagene autoleucel治疗60岁及以上患者复发/难治性B细胞急性淋巴细胞白血病的有效性与安全性

BLOOD
IF23.1
2024-11-051
PRE
Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients

黑人和白人患者急性移植物抗宿主病 (GVHD) 严重程度及其结局的差异

2024-11-011
PRE
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma
2024-07-241
OAAI
The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD
2024-06-282
OAAI
Amphiregulin, ST2, and REG3 α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD
2024-06-140
OAAI